Modular Medical shares surge 11.69% premarket after validating Pivot controller line for Q1 2026 insulin pump commercial launch.

Modular Medical surged 11.69% in premarket trading following the announcement of successful validation of its Pivot controller line for the Q1 2026 launch of its tubeless, removable 3-milliliter patch pump. The milestone confirms manufacturing readiness for high-volume human-use production, addressing a $3 billion market for adult "almost-pumpers." The company emphasized the validation reduces commercialization risks and highlights its scalable, low-cost platform to capture market share. The Pivot, targeting affordability and ease of use, positions Modular Medical to expand access to insulin pump technology, with CEO Jeb Besser noting the achievement reinforces the firm’s ability to scale production efficiently. While regulatory clearance remains pending, the news underscores progress toward commercialization, aligning with the stock’s sharp premarket rise.